Table 2.
Baseline comorbidities for overall combined semaglutide–SGLT2i treatment group
| Comorbidity, n (%) | Combined semaglutide–SGLT2i treatment (overall) n = 11,361 |
|---|---|
| CVD | 9106 (80.2) |
| Coronary heart disease | 7482 (65.9) |
| Hypertension | 7206 (63.4) |
| Dyslipidemia | 7098 (62.5) |
| Diabetic neuropathy | 7077 (62.3) |
| Peripheral vascular disease | 6400 (56.3) |
| Cerebrovascular disease | 3868 (34.0) |
| Diabetic retinopathy | 3788 (33.3) |
| Obesity | 3480 (30.6) |
| Hepatic steatosis | 3265 (28.7) |
| Arrhythmia | 2570 (22.6) |
| CKD | 2010 (17.7) |
| Renal cyst | 767 (6.8) |
| Myocardial infarction | 650 (5.7) |
| Congestive heart failure | 637 (5.6) |
| Kidney stones | 448 (3.9) |
| Sleep apnea | 124 (1.1) |
CKD chronic kidney disease, CVD cardiovascular disease, SGLT2i, sodium–glucose cotransporter-2 inhibitor